The First Affiliated Hospital of Guangdong Pharmaceutical University
Phase
Not applicable
Started
2025-12-30
Last updated
2025-12-24
Condition(s) studied
Prediabetes
Investigational drug(s) / intervention(s)
Diacylglycerol oilColza Oil
Diacylglycerol oil: This study will implement a four-week dietary intervention in which participants assigned to the intervention group will replace their habitual cooking oil with diacylglycerol (DAG) oil. All other lifestyle behaviors will be maintained without modification.
Colza Oil: Participants assigned to the control group will consume colza oil as their cooking oil throughout a four-week dietary intervention. No other lifestyle habits or dietary behaviors will be altered.
Study summary
This study will implement a four-week dietary intervention among middle-aged and older adults with pre-diabetes. Participants assigned to the intervention arm will replace their usual cooking oil with diacylglycerol (DAG) oil, while those in the control arm will consume colza oil. All other lifestyle behaviors will be maintained without modification. The trial will determine the impact of DAG oil consumption on glycemic regulation, lipid metabolism, and body composition in this high-risk population.
Eligibility
Sex
ALL
Min age
40 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria:
1. Aged 40-75 years.
2. Diagnosed with prediabetes according to American Diabetes Association (ADA) criteria: including fasting plasma glucose (FPG) levels of 5.6-6.9 mmol/L, and/or 2-hour postprandial glucose (OGTT-2h) levels of 7.8-11.1 mmol/L, and/or glycated hemoglobin (HbA1c) levels of 5.7%-6.4%.
3. Body mass index (BMI) ≥ 24 kg/m².
4. No plans to relocate or travel extensively in the next three months.
5. Willing to consume all study-provided meals throughout the intervention.
6. Willing and able to provide written informed consent.
Exclusion Criteria:
1. Diagnosis of diabetes (Type 1 or Type 2).
2. Current use of any glucose-lowering medication.
3. Use of appetite suppressants or hormonal medications.
4. History of bariatric surgery, or weight change \>5% in the past 3 months.
5. Alcohol consumption \>40 g/day.
6. Use of antibiotics, probiotics, or prebiotics within the past 3 months.
7. Pregnancy, lactation or planning pregnancy.
8. History of severe cardiovascular disease, malignancy, autoimmune disease, cognitive impairment, or severe dysfunction of thyroid, liver, kidney, or digestive system.
9. Inability to comprehend information, communicate effectively, or comply with the study protocol.
Primary outcome measure(s)
Continuous Glucose Monitoring (CGM) Data — up to 4 weeks At baseline, and 4 weeks, investigators will using Continuous Glucose Monitoring (CGM) to monitor the glucose level of participants.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.